Publication:
Economic evaluation of population-based type 2 diabetes mellitus screening at different healthcare settings in Vietnam

dc.contributor.authorPhung Lam Toien_US
dc.contributor.authorOlivia Wuen_US
dc.contributor.authorMontarat Thavorncharoensapen_US
dc.contributor.authorVaralak Srinonpraserten_US
dc.contributor.authorThunyarat Anothaisintaweeen_US
dc.contributor.authorAmmarin Thakkinstianen_US
dc.contributor.authorNguyen Khanh Phuongen_US
dc.contributor.authorUsa Chaikledkaewen_US
dc.contributor.otherSiriraj Hospitalen_US
dc.contributor.otherMinistry of Health Vitenamen_US
dc.contributor.otherFaculty of Medicine Ramathibodi Hospital, Mahidol Universityen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherCollege of Medical, Veterinary & Life Sciencesen_US
dc.date.accessioned2022-08-04T11:37:26Z
dc.date.available2022-08-04T11:37:26Z
dc.date.issued2021-12-01en_US
dc.description.abstractIntroduction Few economic evaluations have assessed the cost-effectiveness of screening type-2 diabetes mellitus (T2DM) in different healthcare settings. This study aims to evaluate the value for money of various T2DM screening strategies in Vietnam. Methods A decision analytical model was constructed to compare costs and quality-adjusted life years (QALYs) of T2DM screening in different health care settings, including (1) screening at commune health station (CHS) and (2) screening at district health center (DHC), with no screening as the current practice. We further explored the costs and QALYs of different initial screening ages and different screening intervals. Cost and utility data were obtained by primary data collection in Vietnam. Incremental cost-effectiveness ratios were calculated from societal and payer perspectives, while uncertainty analysis was performed to explore parameter uncertainties. Results Annual T2DM screening at either CHS or DHC was cost-effective in Vietnam, from both societal and payer perspectives. Annual screening at CHS was found as the best screening strategy in terms of value for money. From a societal perspective, annual screening at CHS from initial age of 40 years was associated with 0.40 QALYs gained while saving US$ 186.21. Meanwhile, one-off screening was not cost-effective when screening for people younger than 35 years old at both CHS and DHC. Conclusions T2DM screening should be included in the Vietnamese health benefits package, and annual screening at either CHS or DHC is recommended.en_US
dc.identifier.citationPLoS ONE. Vol.16, No.12 December (2021)en_US
dc.identifier.doi10.1371/journal.pone.0261231en_US
dc.identifier.issn19326203en_US
dc.identifier.other2-s2.0-85122005636en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/79177
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85122005636&origin=inwarden_US
dc.subjectMultidisciplinaryen_US
dc.titleEconomic evaluation of population-based type 2 diabetes mellitus screening at different healthcare settings in Vietnamen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85122005636&origin=inwarden_US

Files

Collections